GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$28.68
-0.19 (-0.66%)
▼
5d:
-0.42%
30d:
+0.58%
90d:
+8.43%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GMAB shows positive signals but monitor for confirmation. Market pricing in 2.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GMAB shows positive signals but monitor for confirmation. Market pricing in 2.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$60.41
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$37.51
23.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $28.68, which is considered fair relative to its 30-day fair value range of $27.46 to $29.39. The stock's valuation (Forward PE: 15.3) is in line with its historical norms (16.5). Remarkably, the market is currently pricing in an annual earnings decline of 2.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMAB is in a uptrend. The price is currently testing key support at $27.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $37.96 (+32.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMAB is in a uptrend. The price is currently testing key support at $27.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $37.96 (+32.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$27.46 -
$29.39
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.4% below Wall St target ($37.96)
Trading Range Analysis
30-Day Trading Range
$27.46 -
$29.39
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$27.98
Resistance Level
$29.38
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.26
Wall Street Target
$37.96
(+32.4%)
Revenue Growth (YoY)
25.3%
Earnings Growth (YoY)
-72.8%
Profit Margin
21.1%
Valuation Discount vs History
-2.7% cheaper
PE vs Historical
15.3 vs 16.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.7%
(market-implied from PE analysis)
1-Year Target
$27.91
(-3%)
2-Year Target
$27.15
(-5%)
3-Year Target
$26.42
(-8%)
3-Yr Target (if PE normalizes)
(PE: 15→17)
$28.57
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 42.4%)
$112.59
(+293%)
Base:
(SPY PE: 15.3, Growth: 42.4%)
$82.86
(+189%)
Bear:
(PE: 13.0, Growth: 42.4%)
$70.43
(+146%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 21.87 | Current EPS (TTM): $1.32
Bull Case
$45.23
(+58%)
Analyst growth 42.4%, PE expands to 24.1
Base Case
$41.12
(+43%)
Market implied 42.4%, PE stable at 21.9
Bear Case
$19.63
(-32%)
Severe decline -20.0%, PE contracts to 18.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.3 to 16.5
Stabilization Target:
$31.02
(+8.2%)
PE Expansion Potential:
+8.2%
Share & Embed Analysis
Last updated: August 04, 2026 8:27 AM ET
Data refreshes hourly during market hours. Next update: 9:27 AM
Data refreshes hourly during market hours. Next update: 9:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 59 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 42 HOLD |
